查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961065

全球肿瘤临床试验市场：依阶段类型、研究设计和地区划分 - 市场规模、产业动态、机会分析和预测（2026-2035 年）

Global Oncology Clinical Trials Market: Analysis By Phase Type, Study Design, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球肿瘤临床试验市场正经历显着成长，反映出人们越来越重视开发新型有效的癌症疗法。该市场在 2025 年的价值约为 149.5 亿美元，预计将大幅扩张，到 2035 年达到 256.1 亿美元。这一成长意味着在 2026 年至 2035 年的预测期内，复合年增长率 (CAGR) 为 5.53%，凸显了肿瘤药物研发的持续动能和投资。

推动这一强劲成长的关键因素有很多。其中一个关键驱动因素是全球癌症发生率的上升，这推动了对创新疗法的需求，并加速了临床研究的进程。随着人口老化以及环境和生活方式因素的变化导致癌症发病率上升，发现并儘早引入新疗法的需求变得越来越重要。

市场趋势展望

肿瘤临床试验市场竞争激烈且充满活力，主要特征是大型製药公司之间的激烈竞争，以及积极的整合和策略联盟的形成。这种竞争环境反映了开发突破性癌症疗法的高风险，以及药物成功获准带来的丰厚经济回报。阿斯特捷利康、默克、罗氏和诺华等领先公司已确立了其在该领域的主导地位。

到2025年，这些领先公司将共同控制约35%的肿瘤临床试验项目，这表明它们将在塑造癌症治疗的未来方面发挥重要作用。它们的主导地位不仅源自于雄厚的财力和科学专长，也源自于其在药物开发和市场渗透方面的策略性方法。

  • 例如，阿斯特捷利康已在快速发展的抗体药物偶联物（ADC）领域确立了领先地位。 这项成功主要归功于其突破性的抗体偶联药物 (ADC) Enhart，该药物已在多种癌症类型中展现出显着的临床效益。 核心成长驱动因素 全球癌症发生率的不断上升构成了一项紧迫的医疗保健挑战，大大推动了对新型有效疗法加速研发的需求。由于人口老化、生活方式改变和环境因素的影响，全球癌症发病率持续上升，因此发现创新疗法并将其推向市场的紧迫性日益增强。日益加重的癌症负担不仅影响患者的治疗结果，也给医疗保健系统带来了巨大的压力，要求其提供及时有效的干预措施。 新兴机遇 人工智慧驱动的技术正在迅速改变肿瘤临床试验的关键环节，尤其是在患者招募、方案设计和数据管理方面。这些先进技术为解决长期存在的挑战和效率低下问题提供了新的机遇，这些问题历来阻碍临床研究的进展和成功。人工智慧使试验申办方和研究人员能够简化复杂流程、提高准确性并优化资源分配，最终提升整体效率。
  • 优化障碍
  • 肿瘤临床试验市场面临的最大挑战仍然是病患招募的持续困难。儘管招募足够的受试者对于确保试验的有效性和成功至关重要，但历史上只有一小部分（不到 5%）成年癌症患者参与临床研究。如此低的入组率是药物研发过程中的一个主要瓶颈，减缓了研发进度，并限制了收集关于新型疗法的全面数据的能力。

      目录

      第一章：摘要整理：全球肿瘤临床试验市场

      第二章：报告概述

      • 研究框架
        • 研究目标
        • 市场定义
        • 市场区隔
      • 研究方法
        • 市场规模估算
        • 质性研究
        • 量化研究
        • 依地区划分的原始调查受访者细分
        • 资料三角验证
        • 研究假设

      第三章：全球肿瘤临床试验市场概述

      • 产业价值链分析
        • 药物发现与临床前研究研发
        • 临床试验设计与监理审批
        • 临床试验实施与病患招募
        • 临床试验物资供应与物流
        • 资料分析与监理申报
        • 商业化
      • 行业展望
        • 不断扩充的肿瘤药物研发管线
        • 全球癌症发生率上升
        • 外包给合约研究组织 (CRO) 的趋势日益增长
        • 精准医疗的普及应用
        • 肿瘤临床试验支持的监管
      • PESTLE 分析
      • 波特五力分析
      • 供应商议价能力
      • 买方议价能力
      • 替代品威胁
      • 新进入者威胁
      • 竞争强度
    • 市场成长与展望
      • 市场收入估计与预测（2020-2035 年）
      • 价格分析（以阶段类型划分）
    • 市场吸引力分析
      • 以阶段类型划分
    • 可操作的洞见（分析师建议）

    第四章 竞争格局概览

    • 市场集中度
    • 公司占有率分析（基于价值，2025 年）
    • 竞争格局分析与基准分析

    第五章：全球肿瘤临床试验市场分析

    • 市场动态与趋势
      • 成长驱动因素
      • 限制因素
      • 机遇
      • 关键因素趋势
    • 市场规模及预测（2020-2035）
      • 以阶段类型划分
      • 依研究设计划分
      • 依地区划分

    第六章：北美肿瘤临床试验市场分析

    第七章：欧洲肿瘤临床试验市场分析

    第八章：亚太肿瘤临床试验市场分析

    第九章：中东和非洲肿瘤临床试验市场分析

    第十章：南美洲肿瘤临床试验市场分析

    第11章 企业简介

    • AbbVie Inc.
    • AstraZeneca PLC
    • BeiGene Ltd.
    • Bristol Myers Squibb
    • Charles River Laboratories
    • Clovis Oncology
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • IQVIA
    • ICON plc
    • Johnson &Johnson
    • Labcorp Drug Development
    • Medpace Holdings
    • Merck &Co., Inc.
    • Novartis AG
    • Parexel International
    • Pfizer Inc.
    • Syneos Health
    • Takeda Pharmaceutical
    • Thermo Fisher Scientific
    • Wuxi Clinical CRO
    • Other Prominent Players

    第12章 附录

简介目录
Product Code: AA12251628

The global oncology clinical trials market is witnessing substantial growth, reflecting the increasing focus on developing new and effective cancer treatments. Valued at approximately USD 14.95 billion in 2025, the market is projected to expand significantly, reaching an estimated valuation of USD 25.61 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 5.53% over the forecast period from 2026 to 2035, highlighting the sustained momentum and investment flowing into oncology drug development.

Several key factors are driving this robust expansion. One of the primary contributors is the rising incidence of cancer worldwide, which has prompted greater demand for innovative therapies and accelerated clinical research efforts. As cancer rates climb due to aging populations and changing environmental and lifestyle factors, the urgency to discover and bring forward new treatment options intensifies.

Noteworthy Market Developments

The oncology clinical trials market is highly competitive and dynamic, marked by intense rivalry among leading pharmaceutical companies as well as a trend towards aggressive consolidation and the formation of strategic partnerships. This competitive environment reflects the high stakes involved in developing groundbreaking cancer therapies and the significant financial rewards that come with successful drug approvals. Major players in this arena, such as AstraZeneca, Merck & Co., Roche, and Novartis, have established themselves as dominant forces.

By 2025, these top-tier companies have collectively secured control over approximately 35% of the total oncology clinical trial pipeline, underscoring their influential role in shaping the future of cancer treatment. Their dominance is not only a result of their financial resources and scientific expertise but also a reflection of their strategic approaches to drug development and market penetration.

  • AstraZeneca, for example, has carved out a leadership position in the rapidly evolving Antibody-Drug Conjugate (ADC) segment of oncology. This success is largely attributed to Enhertu, a breakthrough ADC that has demonstrated significant clinical benefits across multiple cancer types.
  • Core Growth Drivers
  • The increasing global prevalence of cancer has become a pressing healthcare challenge, significantly fueling the demand for faster development of new and effective treatments. As cancer incidence rates continue to rise worldwide due to factors such as aging populations, lifestyle changes, and environmental influences, the urgency to discover and bring innovative therapies to market has intensified. This growing burden of cancer not only impacts patient outcomes but also places immense pressure on healthcare systems to provide timely and effective interventions.
  • Emerging Opportunity Trends
  • AI-driven technologies are rapidly transforming key aspects of oncology clinical trials, particularly in the areas of patient recruitment, protocol design, and data management. These advanced technologies offer new opportunities to address longstanding challenges and inefficiencies that have traditionally hindered the pace and success of clinical research. By leveraging artificial intelligence, trial sponsors and researchers can now streamline complex processes, enhance precision, and optimize resource allocation, ultimately contributing to improved overall efficiency.
  • Barriers to Optimization
  • Patient recruitment continues to be the most significant challenge facing the oncology clinical trials market. Despite the critical importance of enrolling sufficient participants to ensure the validity and success of trials, historically, only a small fraction of adult cancer patients-less than 5%-have participated in clinical research. This low enrollment rate poses a major bottleneck in the drug development process, slowing progress and limiting the ability to gather comprehensive data on new treatments.

Detailed Market Segmentation

By phase type, the Phase III studies emerge as the most financially significant segment, representing over 48.89% of the total revenue share. This considerable dominance is largely due to the scale and complexity inherent in Phase III trials, which serve as the pivotal step before a new therapy can receive regulatory approval. Unlike earlier phases, Phase III trials typically involve enrolling a much larger patient population, averaging around 479 participants per study. These trials are conducted across hundreds of sites worldwide, reflecting their global scope and the need to gather extensive data from diverse patient groups to ensure the treatment's safety and efficacy.

By study design, the interventional studies segment holds a commanding position, accounting for more than 71% of the total revenue share within the clinical trials market. This dominance is largely attributable to the intricate and resource-intensive nature of investigational product (IP) dosing intrinsic to interventional studies. Unlike observational studies, which typically involve monitoring and data collection with minimal intervention, interventional trials require meticulous planning, administration, and management of therapeutic agents. These complexities drive higher costs and greater logistical challenges, including the need for specialized personnel, stringent regulatory compliance, and robust patient monitoring protocols, all of which contribute significantly to the revenue generated by this segment.

Segment Breakdown

By Phase Type

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design

  • Interventional Studies
  • Observational Studies
  • Expanded Access Studies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America stands at the forefront of the global oncology clinical trials market, accounting for a dominant share of over 58% of radiation oncology studies as of early 2024. This leadership position underscores the region's significant influence in some of the most lucrative and cutting-edge segments within oncology, particularly radiopharmaceuticals and advanced cellular therapies. The strong presence of world-class research institutions, substantial funding, and a robust regulatory framework contribute to this dominance, fostering an environment conducive to innovation and rapid development of new cancer treatments.
  • Data from recent years highlights the explosive growth in clinical research activities across North America. The total number of registered clinical studies in the region has surged dramatically, increasing from 477,200 in 2023 to an impressive 520,874 by late 2024. Within this vast research landscape, oncology interventions represent a substantial portion, with 68,453 trials dedicated to testing new cancer therapies and approaches. This significant volume of oncology trials reflects both the urgency of addressing cancer as a major health challenge and the region's capacity to conduct complex, large-scale studies.

Leading Market Participants

  • AbbVie Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Charles River Laboratories
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • IQVIA
  • ICON plc
  • Johnson & Johnson
  • Labcorp Drug Development
  • Medpace Holdings
  • Merck & Co., Inc.
  • Novartis AG
  • Parexel International
  • Pfizer Inc.
  • Syneos Health
  • Takeda Pharmaceutical
  • Thermo Fisher Scientific
  • Wuxi Clinical CRO
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Oncology Clinical Trials Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Oncology Clinical Trials Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Drug Discovery & Preclinical Development
    • 3.1.2. Clinical Trial Planning & Regulatory Approval
    • 3.1.3. Clinical Trial Execution & Patient Recruitment
    • 3.1.4. Clinical Trial Supply & Logistics
    • 3.1.5. Data Analysis & Regulatory Submission
    • 3.1.6. Commercialization
  • 3.2. Industry Outlook
    • 3.2.1. Growing Oncology Drug Pipeline
    • 3.2.2. Increasing Cancer Incidence Globally
    • 3.2.3. Rising Outsourcing to CROs
    • 3.2.4. Increasing Adoption of Precision Medicine
    • 3.2.5. Regulatory Support for Oncology Trials
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Pricing Analysis, By Phase Type
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Phase Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Oncology Clinical Trials Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Phase Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Phase I
        • 5.2.1.1.2. Phase II
        • 5.2.1.1.3. Phase III
        • 5.2.1.1.4. Phase IV
    • 5.2.2. By Study Design
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Interventional Studies
        • 5.2.2.1.2. Observational Studies
        • 5.2.2.1.3. Expanded Access Studies
    • 5.2.3. By Region
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. North America
          • 5.2.3.1.1.1. The U.S.
          • 5.2.3.1.1.2. Canada
          • 5.2.3.1.1.3. Mexico
        • 5.2.3.1.2. Europe
          • 5.2.3.1.2.1. Western Europe
            • 5.2.3.1.2.1.1. The UK
            • 5.2.3.1.2.1.2. Germany
            • 5.2.3.1.2.1.3. France
            • 5.2.3.1.2.1.4. Italy
            • 5.2.3.1.2.1.5. Spain
            • 5.2.3.1.2.1.6. Rest of Western Europe
          • 5.2.3.1.2.2. Eastern Europe
            • 5.2.3.1.2.2.1. Poland
            • 5.2.3.1.2.2.2. Russia
            • 5.2.3.1.2.2.3. Rest of Eastern Europe
        • 5.2.3.1.3. Asia Pacific
          • 5.2.3.1.3.1. China
          • 5.2.3.1.3.2. India
          • 5.2.3.1.3.3. Japan
          • 5.2.3.1.3.4. South Korea
          • 5.2.3.1.3.5. Australia & New Zealand
          • 5.2.3.1.3.6. ASEAN
            • 5.2.3.1.3.6.1. Indonesia
            • 5.2.3.1.3.6.2. Malaysia
            • 5.2.3.1.3.6.3. Thailand
            • 5.2.3.1.3.6.4. Singapore
            • 5.2.3.1.3.6.5. Rest of ASEAN
          • 5.2.3.1.3.7. Rest of Asia Pacific
        • 5.2.3.1.4. Middle East & Africa
          • 5.2.3.1.4.1. UAE
          • 5.2.3.1.4.2. Saudi Arabia
          • 5.2.3.1.4.3. South Africa
          • 5.2.3.1.4.4. Rest of MEA
        • 5.2.3.1.5. South America
          • 5.2.3.1.5.1. Argentina
          • 5.2.3.1.5.2. Brazil
          • 5.2.3.1.5.3. Rest of South America

Chapter 6. North America Oncology Clinical Trials Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Phase Type
    • 6.2.2. By Study Design
    • 6.2.3. By Country

Chapter 7. Europe Oncology Clinical Trials Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Phase Type
    • 7.2.2. By Study Design
    • 7.2.3. By Country

Chapter 8. Asia Pacific Oncology Clinical Trials Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Phase Type
    • 8.2.2. By Study Design
    • 8.2.3. By Country

Chapter 9. Middle East & Africa Oncology Clinical Trials Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Phase Type
    • 9.2.2. By Study Design
    • 9.2.3. By Country

Chapter 10. South America Oncology Clinical Trials Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Phase Type
    • 10.2.2. By Study Design
    • 10.2.3. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. AstraZeneca PLC
  • 11.3. BeiGene Ltd.
  • 11.4. Bristol Myers Squibb
  • 11.5. Charles River Laboratories
  • 11.6. Clovis Oncology
  • 11.7. Eli Lilly and Company
  • 11.8. F. Hoffmann-La Roche Ltd
  • 11.9. IQVIA
  • 11.10. ICON plc
  • 11.11. Johnson & Johnson
  • 11.12. Labcorp Drug Development
  • 11.13. Medpace Holdings
  • 11.14. Merck & Co., Inc.
  • 11.15. Novartis AG
  • 11.16. Parexel International
  • 11.17. Pfizer Inc.
  • 11.18. Syneos Health
  • 11.19. Takeda Pharmaceutical
  • 11.20. Thermo Fisher Scientific
  • 11.21. Wuxi Clinical CRO
  • 11.22. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators